Get ready for a mind-bending trip through the world of mental health as Scott Aaronson, M.D., dons his psychedelic lab coat to present “Psychedelics on the Edge: Experiences in Difficult to Treat Depression” at the Psychiatry and Behavioral Sciences Grand Rounds. Aaronson, who doubles as a chief science officer and resident psychiatrist at Sheppard Pratt, is here to enlighten mental health pros on the groovy role psychedelics can play in treating stubborn cases of depression.
Attendees will leave with the superpowers to identify the traits that make someone respond to these treatments, say “no thanks” when a candidate doesn’t fit study criteria, and explain the mystifying mechanisms of these mind-altering substances. Plus, if anyone’s speaking in tongues (or just really fast), interpretation services are just a request away.
In the spirit of transparency, Aaronson’s affiliations with various pharmaceutical consultancies are laid out like cards on a table, along with Nemeroff’s role as the principal investigator for some hefty grants, including those from the National Institutes of Health. He’s tackling everything from alcohol use disorder to PTSD to bipolar disorder—talk about having a full plate!
Rest assured, the CME Advisory Committee is squeaky clean with no financial skeletons in their closets, and any potential conflicts of interest have been thoroughly neutralized.
To sweeten the deal, the University of Texas at Austin Dell Medical School is handing out 1.50 AMA PRA Category 1 Credits™ like candy, ensuring attendees not only expand their minds but also their professional credentials. So, strap in for a psychedelic journey—who knew learning could be this trippy?
Published Date: None